Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealthANPCF Debt-to-EBITDA is -0.34 as of Jun. 2026. The stock has 5 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, CelLBxHealth ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CelLBxHealth's Debt-to-EBITDA or its related term are showing as below:
ANPCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.32 Med: -0.19 Max: -0.11
Current: -0.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of CelLBxHealth was -0.11. The lowest was -0.32. And the median was -0.19.
ANPCF's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs ANPCF: -0.20
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CelLBxHealth Debt-to-EBITDA Related Terms
CelLBxHealth Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANPCF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
CelLBxHealth (ANPCF) has a Debt-to-EBITDA of -0.34 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CelLBxHealth. According to the industry distribution chart, CelLBxHealth ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is CelLBxHealth's Debt-to-EBITDA too high?
CelLBxHealth's current Debt-to-EBITDA is -0.34. Based on the distribution chart, CelLBxHealth ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does CelLBxHealth's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #999999 out of 114 companies for Debt-to-EBITDA. This places CelLBxHealth in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CelLBxHealth. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current Debt-to-EBITDA is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current Debt-to-EBITDA of -0.34. The current Debt-to-EBITDA is -0.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current Debt-to-EBITDA is -0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANPCF has been successfully added to your 
